Ondansetron for the treatment of postfundoplication and dysmotility syndrome-related emesis
Brown, K.A.; Mulberg, A.E.
Gastroenterology 114(4 Part 2): A728
1998
ISSN/ISBN: 0016-5085 Accession: 032640121
Full Text Article emailed within 1 workday: $29.90
Related References
Olver, I.; Paska, W.; Depierre, A.; Seitz, J.F.; Stewart, D.J.; Goedhals, L.; McQuade, B.; McRae, J.; Wilkinson, J.R. 1996: A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group Annals of Oncology: Official Journal of the European Society for Medical Oncology 7(9): 945-952LeBourgeois, J.P.; McKenna, C.J.; Coster, B.; Feyer, P.; Franzén, L.; Goedhals, L.; Marzecki, Z.; Souhami, L.; Stewart, A.; Tønnessen, F.; Haigh, C.; Mitchell, T.; Wilkinson, J.R.; Graham, E. 1999: Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tablet in Radiotherapy Treatment Clinical Oncology 11(5): 340-347
Davidson, N.G.; Paska, W.; Van Belle, S.; Goedhals, L.; McQuade, B.; McRae, J. 1997: Ondansetron suppository: a randomised, double-blind, double-dummy, parallel-group comparison with oral ondansetron for the prevention of cyclophosphamide-induced emesis and nausea. The Ondansetron Suppository emesis study group Oncology 54(5): 380-386
Krzakowski, M.; Graham, E.; Goedhals, L.; Joly, F.; Pawlicki, M.; Rapoport, B.; Yelle, L.; Lees, J.; McQuade, B. 1998: A multicenter, double-blind comparison of I.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. Ondansetron Acute Emesis Study Group Anti-Cancer Drugs 9(7): 593-598
Davidson, N.; Rapoport, B.; Erikstein, B.; L'Esperance, B.; Ruff, P.; Paska, W.; Miller, I.; Curtis, P. 1999: Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study Group Clinical Therapeutics 21(3): 492-502
Dicato, M.A.; Kaasa, S.; Campora, E.; Bleiberg, H.; Warnier, P.; Vindevoghel, A.; Cunningham, D.; Liebhard, A.; Upadhyaya, B.K. 1992: Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: a randomized, single-blind, multicentre study. The Ondansetron International Emesis Study Group Clinical Oncology ) 4(5): 275-279
Gralla, R.J.; Rittenberg, C.; Peralta, M.; Lettow, L.; Cronin, M. 1996: Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin Oncology 53(Suppl): 86-91
Ruff, P.; Paska, W.; Goedhals, L.; Pouillart, P.; Rivière, A.; Vorobiof, D.; Bloch, B.; Jones, A.; Martin, C.; Brunet, R. 1994: Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. the Ondansetron and Granisetron Emesis Study Group Oncology 51(1): 113-118
Chung, F.; Lane, R.; Spraggs, C.; McQuade, B.; Jacka, M.; Luttropp, H.H.; Alahuta, S.; Rocherieux, S.; Roy, M.; Duvaldestin, P.; Curtis, P. 1999: Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group European Journal of Anaesthesiology 16(10): 669-677
Lee, C.W.; Suh, C.W.; Lee, J.S.; Lee, K.H.; Cho, G.Y.; Kim, S.W.; Kim, S.H. 1994: Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis Journal of Korean Medical Science 9(5): 369-375
Haberer, L.J.; Yin, Y.; Palmer, J.L.; Kersey, K.E.; Depee, S.P. 1997: Pharmacodynamic equivalence of 4MG ondansetron IV and 4MG ondansetron IM in the IPECAC-induced emesis model Clinical Pharmacology and Therapeutics 61(2): 170
Cunningham, D.; Gore, M.; Davidson, N.; Miocevich, M.; Manchanda, M.; Wells, N. 1993: The real costs of emesis--an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer European Journal of Cancer 29a (3): 303-306
Huddleston, C.J. 1991: Ondansetron in the treatment of chemotherapy induced emesis Cancer Bulletin 43(2): 175-177
Depierre, A.; Lebeau, B.; d'Allens, H. 1992: A comparison of ondansetron with alizapride plus methylprednisolone in the control of cisplatin-induced emesis. the French Pneumology Group for the Ondansetron Study Oncology 49(4): 305-311
Beck, T.M.; Ciociola, A.A.; Jones, S.E.; Harvey, W.H.; Tchekmedyian, N.S.; Chang, A.; Galvin, D.; Hart, N.E. 1993: Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group Annals of Internal Medicine 118(6): 407-413